CIK 0001512762 · Accelerated filer<br>Smaller reporting company
Coherus Oncology, Inc.
Sign in to watch- Ticker
- CHRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273615821
- Phone
- (650) 649-3530
- Business address
- C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
- Former names
- Coherus BioSciences, Inc., BioGenerics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-07-17 | Anicetti Vincent R Chief Operating Officer | Option exercise | +12,500 | $12.70 | $159K | 63,556 |
| 2020-07-17 | Anicetti Vincent R Chief Operating Officer | Sale | −15,000 | $18.25 | $274K | 48,556 |
| 2020-07-17 | Anicetti Vincent R Chief Operating Officer | Option exercise · Stock Option (Right to Buy) | −2,500 | 17,488 | ||
| 2020-07-17 | Anicetti Vincent R Chief Operating Officer | Option exercise · Stock Option (Right to Buy) | −12,500 | 32,500 | ||
| 2020-07-01 | Lanfear Dennis M President & CEO | Option exercise | +29,994 | $0.01 | $249 | 193,258 |
| 2020-07-01 | Lanfear Dennis M President & CEO | Option exercise · Stock Option (Right to Buy) | −29,994 | 0 | ||
| 2020-06-22 | Szela Mary T Director | Option exercise | +14,997 | $2.50 | $37K | 14,997 |
| 2020-06-22 | Szela Mary T Director | Option exercise | +20,000 | $10.05 | $201K | 34,997 |
| 2020-06-22 | Szela Mary T Director | Option exercise | +20,000 | $12.37 | $247K | 54,997 |
| 2020-06-22 | Szela Mary T Director | Sale | −54,997 | $17.58 | $967K | 0 |
| 2020-06-22 | Szela Mary T Director | Option exercise · Stock Option (Right to Buy) | −14,997 | 0 | ||
| 2020-06-22 | Szela Mary T Director | Option exercise · Stock Option (Right to Buy) | −20,000 | 0 | ||
| 2020-06-22 | Szela Mary T Director | Option exercise · Stock Option (Right to Buy) | −20,000 | 0 | ||
| 2020-06-17 | Anicetti Vincent R Chief Operating Officer | Option exercise | +2,500 | $2.50 | $6K | 51,056 |
| 2020-06-17 | Anicetti Vincent R Chief Operating Officer | Sale | −2,500 | $17.22 | $43K | 48,556 |
| 2020-06-17 | Anicetti Vincent R Chief Operating Officer | Option exercise · Stock Option (Right to Buy) | −2,500 | 19,988 | ||
| 2020-06-17 | Wahlstrom Mats Director | Sale | −200,000 | $17.15 | $3.4M | 0 |
| 2020-05-20 | Viret Jean-Frederic Chief Financial Officer | Sale | −1,278 | $17.66 | $23K | 46,567 |
| 2020-05-18 | Anicetti Vincent R Chief Operating Officer | Sale | −593 | $17.17 | $10K | 48,556 |
| 2020-05-18 | Anicetti Vincent R Chief Operating Officer | Option exercise | +2,500 | $2.50 | $6K | 51,056 |
Page 15 of 39 · 768 trades